H.C. Wainwright initiated coverage of Serina Therapeutics (SER) with a Buy rating and $15 price target The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SER: